Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Research and development - MRTP

Sales, general and administrative

Impairment of intangible assets

Depreciation

Amortization

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

22nd Century Group advances VLN and GVB units towards profitability

22nd Century Group's Q4 2022 earnings call highlighted progress in VLN tobacco and GVB hemp/cannabis units, with plans for multi-state launches and cash positive operations in 2024. Despite challenges like the Grass Valley facility fire, the company remains focused on achieving profitability through revenue growth and market expansion. Key strengths include successful pilot results, volume growth, and a clear path to cash positivity for both business units.

22nd Century Group (XXII) reports strong Q1 performance and growth strategies

22nd Century Group (XXII) showcases strong performance and strategic initiatives to drive revenue growth and achieve cash positivity by 2024.
Despite challenges such as analyst inquiries and insurance impacts, the company's focus on cost efficiencies and margin improvements positions it for success.
Opportunities in revenue growth, bulk ingredient capacity expansion, and margin enhancements present promising prospects for future profitability and market growth.

22nd Century Group reports strong Q2 performance amidst operational challenges

22nd Century Group's Q2 performance showcased growth in sales but faced challenges in gross profit due to production mix shifts.
The company's proactive strategies for cost savings, brand value creation, and gross margin improvement indicate a focus on long-term sustainability.
Despite challenges like VLN rollout delays and tobacco business hurdles, opportunities in market differentiation and efficiency improvements are being pursued.

22nd Century Group pursues profitability through strategic shifts and cost management

22nd Century Group's Q4 2023 earnings call highlighted efforts to achieve profitability by reducing cash burn, focusing on VLN cigarettes for harm reduction, and exploring CMO opportunities in tobacco manufacturing. Despite challenges like decreased net sales and a negative gross profit, the company aims to reach breakeven by Q1 2025.

22nd Century Group reduces cash burn, aims for profitability by 2025

22nd Century Group's Q1 2024 performance reflects progress towards profitability, with improved financial discipline and operational efficiency.
While facing revenue challenges and legal disputes, the company's strategic initiatives and investor support position it for future growth and success.
The focus on reducing losses, strengthening the balance sheet, and expanding market presence underscores the company's commitment to long-term sustainability.

22nd Century Group reports Q2 financial turnaround and growth strategies

22nd Century Group's Q2 2024 performance reflects a notable financial turnaround and progress towards profitability.
Strategic initiatives, leadership appointments, and product strategies position the company for future growth and success.
While challenges remain in achieving cash positive operations, opportunities in market expansion and product innovation offer avenues for continued advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Launches Turn-Key Contract Development and Manufacturing Plus Distribution (CDMO+D) Solution for Industry Leading Hemp/Cannabis Brands

22nd Century Group (XXII) Announces Fully Integrated, Single-Source Strategic License, Manufacturing and Distribution Agreement with Cookies

22nd Century Group, Inc. (XXII) Q4 2022 Earnings Conference Call March 9, 2023 10:00 AM ET Corporate Participants Matt Kreps - Investor Relations Jim Mish - Chief Executive Officer John Miller - President, Tobacco Business Hugh Kinsman - Chief Financial Officer Conference Call Participants Aaron Grey - Alliance Global Partners Vivien Azer - TD Cowen Alex Fuhrman - Craig-Hallum Capital Group Brian Wright - ROTH MKM Jim McIlree - Dawson James Operator Good day, ladies and gentlemen, and welcome to the 22nd Century Group's Fourth Quarter and Year-End Results Conference Call. At this time all lines are in a listen-only mode.

22nd Century Group, Inc. (XXII) Q4 2022 Earnings Call Transcript

22nd Century (XXII) delivered earnings and revenue surprises of -100% and 0.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

22nd Century Group (XXII) Reports Q4 Loss, Lags Revenue Estimates

BUFFALO, N.Y., March 09, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today reported results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent business highlights. The Company will host a live audio webcast today at 10:00 a.m. ET.

22nd Century Group (Nasdaq: XXII) Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Supports Accelerated Expansion of VLN Multi-State Retail Channels, GVB Global Ingredients and CDMO Business Supports Accelerated Expansion of VLN Multi-State Retail Channels, GVB Global Ingredients and CDMO Business

22nd Century Group (XXII) Secures $21 Million Debt Financing to Expand Working Capital for Growth Initiatives

BUFFALO, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced that the Company will be participating in one-on-one meetings during the 35th Annual Roth Conference, to be held March 12-14, 2023 in Orange County, California.

22nd Century Group (Nasdaq: XXII) to Participate in March 2023 Roth Investor Conference

BUFFALO, N.Y., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, will host a live webcast on Thursday, March 9, 2023, at 10:00 AM ET to discuss its 2022 fourth quarter and full year results, which are to be reported in a press release at 6:00 AM ET the same day.

22nd Century Group (Nasdaq: XXII) to Announce Fourth Quarter and Full Year 2022 Results on March 9, 2023

Seeding Program Will Produce Tobacco for Up To 2 Billion Sticks – The Entire Annual Cigarette Consumption of New Zealand – To Make Reduced Nicotine Content Cigarettes Readily Available at National Scale

22nd Century Group (XXII) Accelerates Major Growing Program to Enable Implementation of New Zealand's Reduced-Nicotine Content Tobacco Law

VLN® , a cigarette with 95% less nicotine than conventional cigarettes, is now available for the 75% of Colorad o smokers that are willing to switch brands to help them cut back

Nearly Three Out of Four Colorado Smokers Want to Quit and Now Have a New Option That “Helps You Smoke Less”

Immediately Accretive Addition to the Hemp/Cannabis Business with Positive EBITDA

22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position

Partnership Will Provide Pharmaceutical Grade Cannabinoid Active Ingredients to the Largest Pharmaceutical and Consumer Goods Names in the Industry Partnership Will Provide Pharmaceutical Grade Cannabinoid Active Ingredients to the Largest Pharmaceutical and Consumer Goods Names in the Industry

22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs

Two of the Largest U.S. Convenience Store Distributors Will Support VLN® Rollout into New States and Regions Expects Multiple Retail Chain Customers of Core-Mark and Eby-Brown to Carry 22nd Century's VLN® CigarettesBuffalo, New York--(Newsfile Corp. - January 18, 2023) - 22nd Century Group, Inc.

22nd Century Group (XXII) Announces U.S. Distribution Partnerships with Core-Mark and Eby-Brown

Proposed Menthol Ban Could Leave 22nd Century's VLN® Menthol King as the Only Menthol Cigarette in the $26 Billion U.S. Menthol Market FDA to Advance Reduced Nicotine Content Standards for All Combustible Cigarettes in Q4 2023Paradigm Shift in Tobacco Health Policy and Regulation Expected to Generate Major Gains for Public HealthBuffalo, New York--(Newsfile Corp. - January 17, 2023) - 22nd Century Group, Inc.

FDA's Proposed Menthol Ban Advances to Final Rule Status, Greatly Benefits 22nd Century (XXII) by Affirming the Need for VLN(R) Menthol King as a Critical Off-Ramp for Adult Menthol Smokers

Philadelphia, Pennsylvania--(Newsfile Corp. - January 10, 2023) - A securities fraud class action alleging wrongdoing committed by certain of 22nd Century Group, Inc's (NASDAQ: XXII) Officers and Directors has survived a motion to dismiss the complaint.The underlying case involves an alleged scheme to use undisclosed paid stock promotions to artificially inflate the price of 22nd Century's common stock.

Grabar Law Office Investigates Claims on Behalf of Shareholders of 22nd Century Group, Inc. (XXII) As Securities Fraud Class Action Survives Motion to Dismiss

NEW YORK, NY / ACCESSWIRE / December 16, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with 22nd Century Group. Toni had the pleasure of recently conducting the Interview with John Miller President, 22nd Century Group Inc. (NASDAQ:XXII).

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews John Miller President, 22nd Century Group Inc.

Committed to Supporting New Zealand's Reduced Nicotine Law with Its Tobacco BiotechnologyNew Law Represents Significant Opportunity to Improve National Health through Well Designed Public Policy Framework Believes New Zealand Law Provides a Template for Similar Action in Other Countries, Including the United StatesBuffalo, New York--(Newsfile Corp. - December 13, 2022) -  22nd Century Group, Inc.

22nd Century Group (XXII) Comments on the Advancement of New Zealand's National Reduced Nicotine Content Law

Customer shipments continue uninterrupted, expects to resume production within weeksBuffalo, New York--(Newsfile Corp. - December 8, 2022) - GVB Biopharma, a 22nd Century Group company (NASDAQ: XXII), today provided updates on its operational recovery progress and customer shipments following a fire that occurred at its distillate and isolate manufacturing facility located in Grass Valley, Oregon, on November 20, 2022.

22nd Century Group Provides Update on Grass Valley Facility

Innovative Industrial Properties

Trulieve Cannabis Corp.

All three are pursuing strategies that are working and will work even better in the long term.

3 Best Marijuana Stocks to Buy in December

Established backup plans implemented to ensure continuous customer deliveryBuffalo, New York--(Newsfile Corp. - November 21, 2022) - GVB Biopharma, a 22nd Century Group company (NASDAQ: XXII), today announced that a fire occurred at its GVB Biopharma distillate and isolate manufacturing facility located in Grass Valley, Oregon, on November 20, 2022. There were no reported life threatening injuries, but the fire damaged the facility.

22nd Century Group Provides Update on Incident at Grass Valley Facility

New distribution facility supports rapidly growing demand for hemp/cannabis products New distribution facility supports rapidly growing demand for hemp/cannabis products

22nd Century Group's GVB Biopharma Opens New Central Distribution Facility in The Netherlands

BUFFALO, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company's GVB Biopharma business will attend and be an exhibitor at MJBizCon in Las Vegas on November 16 to 18, 2022.

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas

BUFFALO, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company will be participating in the following investor conferences:

22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Investor Conferences

22nd Century Group, Inc. (NASDAQ:XXII ) Q3 2022 Earnings Conference Call November 8, 2022 10:00 AM ET Company Participants Mei Kuo - Director of Communications and Investor Relations James Mish - Chief Executive Officer John Miller - President, Tobacco Business Hugh Kinsman - Chief Financial Officer Conference Call Participants Vivien Azer - Cowen & Company Aaron Grey - Alliance Global Partners Brian Wright - Roth Capital Partners Jim McIlree - Dawson James Alex Fuhrman - Craig Hallum Operator Welcome to the 22nd Century Group's Third Quarter 2022 Conference Call and Webcast. At this time all participants' have been placed in a listen-only mode and the floor will be opened for your questions following management's prepared remarks.

22nd Century Group, Inc. (XXII) Q3 2022 Earnings Call Transcript

22nd Century (XXII) delivered earnings and revenue surprises of -20% and 1.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

22nd Century Group (XXII) Reports Q3 Loss, Lags Revenue Estimates

BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today reported results for the third quarter ended September 30, 2022, and provided an update on recent business highlights. The Company will host a live audio webcast today at 10:00 a.m. E.T.

News for 22nd Century Group Stock (XXII)